Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy

Practice and outcome analysis in a series of 2237 patients from 11 institutions

Gianni Fellin, Maria Mirri, Luigi Santoro, Barbara Alicja Jereczek-Fossa, Claudio Divan, Salvatore Mussari, Francesco Ziglio, Beniamino La Face, F. Barbera, Michela Buglione, Laura Bandera, Barbara Ghedi, Nadia Di Muzio, Andrea Losa, Paola Mangili, L. Nava, Renato Chiarlone, Nunzia Ciscognetti, Emilio Gastaldi, Federica Cattani & 23 others Ruggero Spoto, Andrea Vavassori, Francesca R. Giglioli, Alessia Guarneri, Valentina Cerboneschi, Marcello Mignogna, Mauro Paoluzzi, Valentina Ravaglia, C. Chiumento, Stefania Clemente, Vincenzo Fusco, Roberto Santini, M. Stefanacci, Francesco P. Mangiacotti, Marco Martini, Tiziana Palloni, Giuseppe Schinaia, G. Lazzari, Giovanni Silvano, S. M. Magrini, Umberto Ricardi, Riccardo Santoni, Roberto Orecchia

Research output: Contribution to journalArticle

Abstract

Objective: Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Methods: Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community andacademic hospitals were treated with iodine- 125 (125I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. 125I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failurefree survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Results: Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p<0.0001) and V100 (p=0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p=0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. Conclusion: This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Advances in knowledge: Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.

Original languageEnglish
Article number20150981
JournalBritish Journal of Radiology
Volume89
Issue number1065
DOIs
Publication statusPublished - 2016

Fingerprint

Brachytherapy
Italy
Prostatic Neoplasms
Survival
Community Hospital
Palladium
Iodine
Seeds
Multivariate Analysis
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy : Practice and outcome analysis in a series of 2237 patients from 11 institutions. / Fellin, Gianni; Mirri, Maria; Santoro, Luigi; Jereczek-Fossa, Barbara Alicja; Divan, Claudio; Mussari, Salvatore; Ziglio, Francesco; La Face, Beniamino; Barbera, F.; Buglione, Michela; Bandera, Laura; Ghedi, Barbara; Di Muzio, Nadia; Losa, Andrea; Mangili, Paola; Nava, L.; Chiarlone, Renato; Ciscognetti, Nunzia; Gastaldi, Emilio; Cattani, Federica; Spoto, Ruggero; Vavassori, Andrea; Giglioli, Francesca R.; Guarneri, Alessia; Cerboneschi, Valentina; Mignogna, Marcello; Paoluzzi, Mauro; Ravaglia, Valentina; Chiumento, C.; Clemente, Stefania; Fusco, Vincenzo; Santini, Roberto; Stefanacci, M.; Mangiacotti, Francesco P.; Martini, Marco; Palloni, Tiziana; Schinaia, Giuseppe; Lazzari, G.; Silvano, Giovanni; Magrini, S. M.; Ricardi, Umberto; Santoni, Riccardo; Orecchia, Roberto.

In: British Journal of Radiology, Vol. 89, No. 1065, 20150981, 2016.

Research output: Contribution to journalArticle

Fellin, G, Mirri, M, Santoro, L, Jereczek-Fossa, BA, Divan, C, Mussari, S, Ziglio, F, La Face, B, Barbera, F, Buglione, M, Bandera, L, Ghedi, B, Di Muzio, N, Losa, A, Mangili, P, Nava, L, Chiarlone, R, Ciscognetti, N, Gastaldi, E, Cattani, F, Spoto, R, Vavassori, A, Giglioli, FR, Guarneri, A, Cerboneschi, V, Mignogna, M, Paoluzzi, M, Ravaglia, V, Chiumento, C, Clemente, S, Fusco, V, Santini, R, Stefanacci, M, Mangiacotti, FP, Martini, M, Palloni, T, Schinaia, G, Lazzari, G, Silvano, G, Magrini, SM, Ricardi, U, Santoni, R & Orecchia, R 2016, 'Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: Practice and outcome analysis in a series of 2237 patients from 11 institutions', British Journal of Radiology, vol. 89, no. 1065, 20150981. https://doi.org/10.1259/bjr.20150981
Fellin, Gianni ; Mirri, Maria ; Santoro, Luigi ; Jereczek-Fossa, Barbara Alicja ; Divan, Claudio ; Mussari, Salvatore ; Ziglio, Francesco ; La Face, Beniamino ; Barbera, F. ; Buglione, Michela ; Bandera, Laura ; Ghedi, Barbara ; Di Muzio, Nadia ; Losa, Andrea ; Mangili, Paola ; Nava, L. ; Chiarlone, Renato ; Ciscognetti, Nunzia ; Gastaldi, Emilio ; Cattani, Federica ; Spoto, Ruggero ; Vavassori, Andrea ; Giglioli, Francesca R. ; Guarneri, Alessia ; Cerboneschi, Valentina ; Mignogna, Marcello ; Paoluzzi, Mauro ; Ravaglia, Valentina ; Chiumento, C. ; Clemente, Stefania ; Fusco, Vincenzo ; Santini, Roberto ; Stefanacci, M. ; Mangiacotti, Francesco P. ; Martini, Marco ; Palloni, Tiziana ; Schinaia, Giuseppe ; Lazzari, G. ; Silvano, Giovanni ; Magrini, S. M. ; Ricardi, Umberto ; Santoni, Riccardo ; Orecchia, Roberto. / Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy : Practice and outcome analysis in a series of 2237 patients from 11 institutions. In: British Journal of Radiology. 2016 ; Vol. 89, No. 1065.
@article{f5a1d63bdce049f2a0da10f346fb4bc1,
title = "Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: Practice and outcome analysis in a series of 2237 patients from 11 institutions",
abstract = "Objective: Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Methods: Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community andacademic hospitals were treated with iodine- 125 (125I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. 125I seeds were implanted in 97.7{\%} of the patients: the mean dose received by 90{\%} of target volume was 145Gy; the mean target volume receiving 100{\%} of prescribed dose (V100) was 91.1{\%}. Biochemical failurefree survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Results: Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98{\%}, 94 and 89{\%}, and 92 and 88{\%}, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p<0.0001) and V100 (p=0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p=0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. Conclusion: This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Advances in knowledge: Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.",
author = "Gianni Fellin and Maria Mirri and Luigi Santoro and Jereczek-Fossa, {Barbara Alicja} and Claudio Divan and Salvatore Mussari and Francesco Ziglio and {La Face}, Beniamino and F. Barbera and Michela Buglione and Laura Bandera and Barbara Ghedi and {Di Muzio}, Nadia and Andrea Losa and Paola Mangili and L. Nava and Renato Chiarlone and Nunzia Ciscognetti and Emilio Gastaldi and Federica Cattani and Ruggero Spoto and Andrea Vavassori and Giglioli, {Francesca R.} and Alessia Guarneri and Valentina Cerboneschi and Marcello Mignogna and Mauro Paoluzzi and Valentina Ravaglia and C. Chiumento and Stefania Clemente and Vincenzo Fusco and Roberto Santini and M. Stefanacci and Mangiacotti, {Francesco P.} and Marco Martini and Tiziana Palloni and Giuseppe Schinaia and G. Lazzari and Giovanni Silvano and Magrini, {S. M.} and Umberto Ricardi and Riccardo Santoni and Roberto Orecchia",
year = "2016",
doi = "10.1259/bjr.20150981",
language = "English",
volume = "89",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1065",

}

TY - JOUR

T1 - Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy

T2 - Practice and outcome analysis in a series of 2237 patients from 11 institutions

AU - Fellin, Gianni

AU - Mirri, Maria

AU - Santoro, Luigi

AU - Jereczek-Fossa, Barbara Alicja

AU - Divan, Claudio

AU - Mussari, Salvatore

AU - Ziglio, Francesco

AU - La Face, Beniamino

AU - Barbera, F.

AU - Buglione, Michela

AU - Bandera, Laura

AU - Ghedi, Barbara

AU - Di Muzio, Nadia

AU - Losa, Andrea

AU - Mangili, Paola

AU - Nava, L.

AU - Chiarlone, Renato

AU - Ciscognetti, Nunzia

AU - Gastaldi, Emilio

AU - Cattani, Federica

AU - Spoto, Ruggero

AU - Vavassori, Andrea

AU - Giglioli, Francesca R.

AU - Guarneri, Alessia

AU - Cerboneschi, Valentina

AU - Mignogna, Marcello

AU - Paoluzzi, Mauro

AU - Ravaglia, Valentina

AU - Chiumento, C.

AU - Clemente, Stefania

AU - Fusco, Vincenzo

AU - Santini, Roberto

AU - Stefanacci, M.

AU - Mangiacotti, Francesco P.

AU - Martini, Marco

AU - Palloni, Tiziana

AU - Schinaia, Giuseppe

AU - Lazzari, G.

AU - Silvano, Giovanni

AU - Magrini, S. M.

AU - Ricardi, Umberto

AU - Santoni, Riccardo

AU - Orecchia, Roberto

PY - 2016

Y1 - 2016

N2 - Objective: Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Methods: Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community andacademic hospitals were treated with iodine- 125 (125I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. 125I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failurefree survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Results: Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p<0.0001) and V100 (p=0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p=0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. Conclusion: This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Advances in knowledge: Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.

AB - Objective: Low-dose-rate brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure. Methods: Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community andacademic hospitals were treated with iodine- 125 (125I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. 125I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failurefree survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes. Results: Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p<0.0001) and V100 (p=0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p=0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT. Conclusion: This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer. Advances in knowledge: Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.

UR - http://www.scopus.com/inward/record.url?scp=84989912722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989912722&partnerID=8YFLogxK

U2 - 10.1259/bjr.20150981

DO - 10.1259/bjr.20150981

M3 - Article

VL - 89

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1065

M1 - 20150981

ER -